December 19, 2012
Our health care roundtable gathers the Motley Fool's top health care analysts to discuss the sector's biggest stories in a free flowing and highly opinionated format.
In this portion of the video, the guys discuss one of Johnson & Johnson's (NYSE: JNJ ) major acquisitions in the medical devices space and whether it was a good idea considering that the company has seen some slowdown in that area. They discuss the huge potential with rapidly growing emerging markets and the difficulty in tapping those markets when the people there simply don't have as much money to spend.
In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. Offering everything from baby powder to biologics, critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand new premium report on Johnson & Johnson. To claim your copy simply click here now for instant access.